Beam Therapeutics expects cash runway to support operating plans into mid-2029

Beam Therapeutics expects its cash runway to support operating plans into mid-2029. That extends the company's funding horizon and reduces the near-term need for new capital if spending stays on plan. The update did not include the cash balance, burn rate or assumptions behind the runway estimate.